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a b s t r a c t
Oxaliplatin, a platinum-based chemotherapeutic drug, frequently induces peripheral neuropathy.
Accumulating evidences suggest a possible relationship between peripheral vascular impairment and
peripheral neuropathy. In this study, we investigated the effects of vasodilators on cumulative peripheral
neuropathy induced by repeated injections of oxaliplatin (10 mg/kg) once a week for 8 weeks in mice.
Single injections of vasodilators, including a phosphodiesterase type 5 inhibitor tadalafil acutely allevi-
ated oxaliplatin-induced cold hypersensitivity, while tadalafil had no effect on the mechanical hyper-
sensitivity. By contrast, long-term administration of tadalafil (0.1% in chow diets) during the oxaliplatin
injection period reduced the oxaliplatin-induced decreases in skin temperature and blood flow without
affecting platinum concentrations in blood, sciatic nerves, and dorsal root ganglion. The long-term
administration significantly suppressed cold, mechanical, and electrical current hypersensitivities as
well as thermal hypoesthesia. Furthermore, it prevented the decreases in sensory nerve conductance
velocity and the number of endoneurial microvessels, and axon degeneration in the sciatic nerves.
In vitro studies confirmed that tadalafil does not interfere with the cytotoxicity of oxaliplatin against
human cancer cell lines. Altogether, these results suggest that improvement of peripheral vascular
impairment by tadalafil could alleviate and prevent oxaliplatin-induced peripheral neuropathy.
© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Oxaliplatin (L-OHP) is a platinum-based chemotherapeutic drug
widely used to treat colorectal, gastric, and pancreatic cancers.
However, it rapidly induces acute peripheral neuropathy in 85e96%
of patients, although it is usually improved within a week.
Furthermore, cumulative peripheral neuropathy, with paresthesia,
dysesthesia, numbness and pain in the hands and/or feet, occurs in
40e93% of patients who have undergone multiple chemotherapy
cycles.1 This cumulative L-OHP-induced peripheral neuropathy
(OIPN) diminishes the activities of daily living and quality of life in
patients with cancer, often resulting in dosage reduction and delay
or even discontinuation of chemotherapy in severe cases.1e3
Nevertheless, there are no or little effective strategies for pre-
venting or treating OIPN.3,4
Endoneurial microvascular dysfunction is observed in patients
and animal models with peripheral neuropathy.5,6 Moreover, pe-
ripheral nerve dysfunction in diabetic patients and animal models
is preceded by impaired vascular reactivity, which is thus consid-
ered an early diagnostic marker and predictor of the severity of
diabetic neuropathy.7e9 Vascular impairment of peripheral arterial
diseases is responsible for the induction of sensory disturbance in
the early stage, with increasing pain as disease progresses.10e12
Similarly, experimental animals in which peripheral blood flow in
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the hindlimbs is restricted exhibit spontaneous and evoked pain
behaviors as well as tactile hypoesthesia.13e15 The association be-
tween peripheral vascular impairment and peripheral neuropathy
is further supported by studies showing that vasodilators, such as
phosphodiesterase (PDE) inhibitors,16e18 prostaglandin analogs,19
and endothelin (ET) receptor antagonists,20 improve peripheral
vascular impairment but also attenuate neural dysfunction, nerve
degeneration, hypoesthesia, and painful behaviors in animal
models of diabetes. These findings propose the possibility that
improvement of peripheral vascular impairment by vasodilators
may be a potential preventive and/or therapeutic strategy for pe-
ripheral neuropathy accompanying peripheral vascular
impairment.
Peripheral blood flow is reduced also in L-OHP-treated ani-
mals.21,22 Gauchan et al. further reported that persistent improve-
ment of peripheral vascular impairment by a prostaglandin E1
analog attenuated the mechanical hypersensitivity evoked by a
single administration of L-OHP in mice.21 However, detailed ana-
lyses for the efficacy of vasodilators on the cumulative OIPN are still
lacking. In the present study, we examined the acute alleviative and
preventive effects of vasodilators on the cumulative OIPN in mice.
Here, we found that tadalafil, a PDE type 5 inhibitor, has good ef-
ficacy against cumulative OIPN. This drug alleviated cold hyper-
sensitivity acutely, but prevented a wide range of symptoms,
sensory nerve dysfunction and degeneration observed in cumula-
tive OIPN.
2. Materials and methods
2.1. Details are presented in supplementary materials and methods
2.1.1. Animals
C57BL/6J mice (Japan SLC, Shizuoka, Japan) aged 6e7 weeks
were housed at 24 ± 1 C and 55 ± 10% humidity under a 12 h light/
dark cycle with ad libitum access to water and MF chow (Oriental
Yeast, Tokyo, Japan). The experimental protocols used in this study
were approved by the Kyoto University Animal Research Commit-
tee (permit number 13e38) and performed in accordance with
their ethical guidelines.
2.1.2. Experimental design
To investigate the acute effects of vasodilators, mice received
intraperitoneal (i.p.) injections of L-OHP (10 mg/kg body weight
[Wako Pure Chemical Industries, Osaka, Japan]) or vehicle (5%
glucose solution) once a week for 4e6 weeks. Skin blood flow and
cold and mechanical sensitivities (see below) were measured
before and after the following drugs were administered: tadalafil
(10 mg/kg [Combi-Blocks, San Diego, CA], dissolved in 10% DMSO
and 20% polyethylene glycol 400 in distilled water), i.p., 1 h before
testing; limaprost alfadex (0.3 mg/kg [Ono Pharmaceutical Co.,
Osaka, Japan] in saline) per os, 0.5 h before testing; bosentan
(30 mg/kg [Toronto Research Chemicals, Toronto, Canada] in sa-
line), i.p., 4 h before testing; vehicle, i.p., 1 h before testing.
To investigate the preventive effects of tadalafil, mice receiving
i.p. injections of L-OHP (10 mg/kg) or vehicle once a week for 8
weeks were fed chow containing 0.1% (w/w) tadalafil (Oriental
Yeast) ad libitum from the day before starting to the end of repeated
injections (8 weeks). Skin blood flow and temperature, cold, me-
chanical, and current stimulation sensitivities, and nerve conduc-
tion velocities (NCVs) were measured after 8 weeks (see below).
2.1.3. Physiological analyses
Skin blood flow through the plantar surface of the hindpaw was
measured using a small laser Doppler blood flow sensor (RBF-101;
Pioneer, Tokyo, Japan), and the temperature was measured with a
skin surface probe connected to a thermometer (BAT-10 multi-
purpose thermometer; Physitemp Instruments, Clifton NJ). Sensory
and motor NCVs in the tail were recorded with an amplifier (EX-1;
AD Instruments, Milford, MA) in response to electrical stimulation
(STG4002; Multi Channel Systems, Reutlingen, Germany) and
processed with LabChart8 software (AD Instruments).
2.1.4. Behavioral tests
Cold sensitivity was assessed by quantifying cold-escape be-
haviors for 60 s after acetone (10 ml) was applied to the plantar skin
of the hind paw. Mechanical sensitivity was assessed by measuring
the paw withdrawal threshold against stimulation with von Frey
filaments (Stoelting, Wood Dale, IL). Thermal sensitivity was
assessed by measuring the time to withdraw a paw exposed to a
radiant heat source from aHargreaves apparatus (Ugo Basile, Milan,
Italy). Paw withdrawal thresholds to transcutaneous current stim-
uli were measured using a Neurometer CPT/C (Neurotron Inc.,
Baltimore, MD).
2.1.5. Immunohistochemistry
Immunohistochemistry for CD31, a platelet-endothelial cell
adhesion molecule highly expressed in the vascular endothelial
cells, was performed with 6 mm-thick sciatic nerves sections incu-
bated with CD31 antibody (1:100; BD Bioscience, Franklin Lakes,
NJ). The density of CD31þ vessels (count/mm2) was calculated.
2.1.6. Electron microscopy
Sciatic nerves fixed in 2% glutaraldehyde and 4% para-
formaldehyde and postfixed in 1% osmium tetroxide were
sectioned (70 nm) and imaged with a transmission electron mi-
croscope (H7650; Hitachi, Tokyo, Japan). The axons were classified
by calculating the circularity and analyzed with MetaMorph
software.
2.1.7. Platinum concentration
The concentrations of platinum in blood, sciatic nerve, and
dorsal root ganglia (DRG) samples were measured with an Agilent
7700x ICP-MS system (Agilent Technologies, Santa Clara, CA).
2.1.8. Cytotoxicity assay
The cytotoxicity of L-OHP to human colon cancer (HCT116) and
stomach adenocarcinoma (AGS) cell lines (ATCC, Manassas, VA) was
assessed with an MTT assay.
2.1.9. Statistical analysis
Differences were compared using Student's t tests for two
groups and one-way or two-way analyses of variance (ANOVA)
followed by an appropriate post hoc test for more than two groups.
Statistical analyses of the 50% withdrawal thresholds in von Frey
filament testing were performed using ManneWhitney U test or
KruskaleWallis test followed by Dunn's post hoc test for each day.
Other time-course data were analyzed by two-way ANOVA for
repeated measures followed by Tukey's post hoc test. In all cases,
differences of P < 0.05 were considered statistically significant.
3. Results
3.1. Acute alleviative effects of vasodilators on L-OHP-induced
peripheral vascular impairment and cold hypersensitivity
Skin blood flow through the hindpaw was measured before and
after various vasodilators were administered to mice treated with
L-OHP or vehicle for 4 weeks (Fig. 1A). Skin blood flow was
significantly reduced by repeated injections of L-OHP. A single
administration of the PDE5 inhibitor tadalafil (10 mg/kg), the
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prostaglandin E1 analog limaprost alfadex (0.3 mg/kg), and the ET
receptor antagonist bosentan (30 mg/kg) significantly recovered
the decreased skin blood flow in L-OHP-treated mice. A single
administration of tadalafil also significantly increased the skin
blood flow in the vehicle-treated mice.
The frequency of licking and shaking in response to an acetone
application was increased in mice treated with L-OHP for 5 weeks.
The cold hypersensitivity was significantly attenuated by a single
administration of tadalafil, limaprost alfadex, and bosentan
(Fig. 1B). The 50% withdrawal threshold to von Frey filaments were
decreased in mice treated with L-OHP for 6 weeks. However, the
mechanical hypersensitivity was not affected by a single adminis-
tration of tadalafil (Fig. 1C).
3.2. Long-term administration of tadalafil improves peripheral
vascular impairment in L-OHP-treated mice
We selected tadalafil for subsequent experiments because of its
relatively long half-life and vasodilatory effects among the tested
vasodilator drugs. We first verified that oral long-term adminis-
tration of tadalafil did not affect the blood concentration and tissue
accumulation of L-OHP in mice. The concentrations of platinum in
blood and tissue samples, sciatic nerves and DRG, from mice fed a
chow for 8weeks containing 0.1% [w/w] tadalafil did not differ from
those on the control (normal) diet (Table 1).
Repeated injections of L-OHP significantly reduced body weight.
Long-term administration of tadalafil did not influence the body
weight in repeated vehicle- and L-OHP-treated mice (Fig. 2A).
Repeated L-OHP injections gradually and significantly reduced skin
blood flow through the hindpaw. Significant reductions were
observed between 4 and 8 weeks after the L-OHP injections.
Tadalafil tended to increase the skin blood flow in the repeated
vehicle-treatedmice, and it significantly prevented the reduction in
the repeated L-OHP-treated mice (Fig. 2B). Accordingly, skin tem-
perature in the hindpaw was significantly lowered 8 weeks after
the repeated L-OHP injections. The reduction of skin temperature
was significantly prevented by tadalafil (Fig. 2C).
3.3. Long-term tadalafil prevents L-OHP-induced cold, mechanical,
and current hypersensitivities and thermal hypoesthesia in L-OHP-
treated mice
Repeated injections of L-OHP significantly increased the fre-
quency of licking and shaking in response to acetone application,
which developed within 2 weeks. The L-OHP-induced cold hyper-
sensitivity was significantly prevented by long-term administration
of tadalafil (Fig. 3A). Similarly, repeated L-OHP injections signifi-
cantly decreased the 50% withdrawal threshold to mechanical
stimulation between 2 and 8 week. The mechanical
Fig. 1. Acute effects of vasodilators on L-OHP-induced peripheral vascular impairment and
peripheral neuropathy. Oxaliplatin (L-OHP; 10 mg/kg) or its vehicle (Veh) was injected
intraperitoneally once a week for 4e6 weeks. Skin blood flow in the hind paw (A) and
cold sensitivity (B) were assessed before (pre) and after (post) administration of
tadalafil (TDF; 10 mg/kg, i.p., 1 h before testing), limaprost alfadex (LMP; 0.3 mg/kg, per
os, 0.5 h before testing), or bosentan (BST; 30 mg/kg, i.p., 4 h before testing) 4 and 5
weeks after the repeated injections, respectively. Skin blood flow (ml/min) in the hind
paw was measured by using a small laser Doppler blood flow sensor. The frequency of
cold-escape behaviors (licking and shaking) were measured for 60 s in response to an
application of acetone. The results are expressed as means ± S.E.M. (n ¼ 4e6).
**P < 0.01, ***P < 0.001 compared with the pre-values of vehicle-treated mice (un-
paired t test); #P < 0.05, ##P < 0.01 (paired t test); n.s., not significant. (C) The 50%
withdrawal thresholds to mechanical stimulation with von Frey filaments were
measured before (pre) and 1 h after (post) an administration of tadalafil (TDF; 10 mg/
kg, i.p.) after 6 weeks of repeated injections of vehicle or L-OHP (n ¼ 5e6). **P < 0.01
compared with the pre values of vehicle-treated mice (ManneWhitney U-test).
Table 1
Effect of tadalafil on platinum concentrations in L-OHP-treated mice.
Sample type Platinum concentration (nmol/mL or nmol/g)
L-OHP L-OHP þ TDF
Blood plasma 0.85 ± 0.15 0.92 ± 0.11
Sciatic nerves 4.21 ± 0.72 5.66 ± 1.31
DRG 5.55 ± 0.69 6.45 ± 0.15
L-OHP (10 mg/kg) was injected i.p. once a week for 8 weeks, during which mice
were fed normal chow or a chow diet containing 0.1% tadalafil (TDF). Blood samples,
sciatic nerves, and dorsal root ganglia (DRG) at L4eL6 were isolated from each
group, and platinum concentrations were analyzed using an ICP-MS system. The
results are expressed as means ± S.E.M (n ¼ 4e5).
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hypersensitivity was significantly attenuated by long-term tadalafil
administration (Fig. 3B). By contrast, repeated injections of L-OHP
for 8 weeks significantly prolonged the latency of thermal noci-
ceptive responses. The thermal hypoesthesia, a symptom of cu-
mulative peripheral neuropathy,22 was significantly prevented by
long-term tadalafil administration (Fig. 3C).
We measured current perception thresholds to sine-wave pul-
ses of 5, 250, and 2000 Hz produced by a Neurometer to stimulate
C, Ad, and Ab fibers, respectively. Current perception thresholds at
these frequencies were significantly decreased by repeated L-OHP
injections for 8 weeks. Long-term tadalafil administration pre-
vented these decreases at any frequencies (Fig. 3DeF).
3.4. Long-term tadalafil preserves sensory NCV in L-OHP-treated
mice
We measured sensory and motor NCVs in the tails of mice
receiving repeated L-OHP injections for 8 weeks. Sensory NCV was
significantly reduced in mice treated with L-OHP. Long-term
tadalafil administration prevented the decrease in sensory NCV
(Fig. 4A). L-OHP treatment also reduced motor NCV, but this
decrease and the effect of tadalafil were not significant (Fig. 4B).
3.5. Long-term tadalafil prevents L-OHP-induced decreases in
endoneurial microvessel density in sciatic nerves
Immunostaining for CD-31, an endothelial marker, was per-
formed on sciatic nerve sections from mice receiving repeated L-
OHP injections for 8 weeks (Fig. 5A). Quantitative analysis of
confocal images showed that the density of CD31-immunoreactive
microvessels was significantly reduced by L-OHP, which was pre-
vented by long-term administration of tadalafil (Fig. 5B).
3.6. Long-term tadalafil prevents L-OHP-induced axon
degeneration in sciatic nerves
Electron microscopy of sciatic nerve sections revealed a
degeneration of myelinated fibers with abnormal distorted
morphology in mice receiving repeated L-OHP injections for 8
weeks (Fig. 6A). The percentage of axons with a circularity measure
of >0.7 (indicative of normal axon morphology) was significantly
reduced in L-OHP-treated mice. Consistently, the percentage of
axons with a circularity of <0.5 (indicative of severe axonal
degeneration) was significantly increased in these mice. Long-term
tadalafil administration tended to prevent the changes in the dis-
tribution of axon circularities (Fig. 6B).
3.7. Tadalafil does not affect the cytotoxicity of L-OHP in human
cancer cells
To verify that tadalafil did not impact the cytotoxicity of L-OHP
on cancer cells, we performed in vitro MTT assays. The viability of
HCT116 and AGS cells was not altered by exposure to various con-
centrations of tadalafil (up to 10 mM) for 24 h. Furthermore, tadalafil
did not alter the reduced viability of cell lines exposed to 10 mM L-
OHP for 24 h (Fig. 7). Thus, the above-described effects of tadalafil
on L-OHP-induced peripheral neuropathy did not interferewith the
ability of L-OHP to kill cancer cells.
4. Discussion
In the present study, we provided evidences that improvement
of peripheral vascular impairment by tadalafil, a PDE5 inhibitor,
showed acute alleviative and preventive effects on OIPN. A single
administration of tadalafil exerted limited efficacy on cold hyper-
sensitivity, but not on mechanical hypersensitivity. However, long-
term administration of tadalafil had wide range effects on signs,
symptoms and pathophysiological changes observed in OIPN
model mice.
Patients treated with cumulative doses of L-OHP experience
multiple sensory disturbances; cold hypersensitivity, but
Fig. 2. Effects of tadalafil and L-OHP on body weight and peripheral vascular impairment.
L-OHP (10 mg/kg) or its vehicle (Veh) was injected i.p. once a week for 8 weeks, during
which mice were fed normal chow or a chow diet containing 0.1% tadalafil (TDF). Body
weight (A) and skin blood flow through the hindpaw (B) were measured before and
weekly or biweekly (n ¼ 4e6). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the
vehicle-treated mice without tadalafil; ##P < 0.01, ###P < 0.001 compared with the L-
OHP-treated mice without tadalafil (Tukey's post hoc test following two-way repeated
measured ANOVA). (C) Skin temperature in the hind paw was measured after 8 weeks
of repeated injections (n ¼ 8). ***P < 0.001 (Tukey's post hoc test following one-way
ANOVA). The results are expressed as means ± S.E.M.
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concomitantly also hypoesthesia in warm, cool, touch and bump
detection,23 accompanied by a reduction of NCV.24 However, there
are no reliable animal models of OIPN, in which such sensory dis-
turbances can be appropriately assessed. Mechanical and cold hy-
persensitivities have been frequently documented in animals
receiving relatively low-doses of L-OHP (2e5 mg/kg) once or
several times a week.22,25e27 However, mice treated with these
doses in our preliminary experiments did not exhibit thermal
hypoesthesia, reduced NCV, or axonal degeneration (data not
shown). In this study, we selected relatively higher-dose of L-OHP
(10mg/kg) once aweek for 4e8weeks. It enabled us to examine the
effects of test drugs on abnormal sensations (mechanical/cold/
current hypersensitivity and thermal hypoesthesia), neurological
dysfunction and axon degeneration, although it caused the
decrease in body weight.
Consistent with the previous experiments in animals21,22 and
patients,23 peripheral blood flowwas gradually reduced along with
increasing cumulative doses of L-OHP, and it was accompanied
with the reduction in skin temperature. Although the mechanisms
underlying the peripheral vascular impairment are largely un-
known, L-OHP can directly and/or indirectly affect vascular endo-
thelial function,28 and L-OHP-based chemotherapy induces
vascular endothelial injury in colorectal cancer patients.29,30 It is
possible that the vascular endothelial injury and dysfunction
induced by L-OHP may lead to the peripheral vascular impairment.
In the present study, mechanical hypersensitivity was invariably
observed during the observation period. By contrast, cold hyper-
sensitivity was gradually exacerbated along with increasing cu-
mulative doses of L-OHP, which was likely paralleled by the
progression of peripheral vascular impairment. L-OHP can induce
rapid-onset cold hypersensitivity, a characteristic symptom of
acute OIPN, within several hours after the injection.26,27,31 We and
other groups previously found that it is mediated through an L-OHP
metabolite, oxalate,27,31 which indirectly sensitizes a redox-
sensitive nociceptor, transient receptor potential ankyrin 1
(TRPA1), against cold temperature.32,33 However, as the cold hy-
persensitivity usually improves within a week, cumulative doses of
L-OHP escalate the cold hypersensitivity through other mecha-
nisms. In this study, three different vasodilators, namely, tadalafil,
limaprost alfadex, and bosentan, attenuated the cold hypersensi-
tivity while improving skin blood flow. These findings suggest that
Fig. 3. Effects of tadalafil on L-OHP-induced cold, mechanical, and current hypersensitivities and thermal hypoesthesia. L-OHP (10 mg/kg) or its vehicle (Veh) was injected i.p. once a
week for 8 weeks, during which mice were fed normal chow or a chow diet containing 0.1% tadalafil (TDF). Cold (A, n ¼ 6e11) and mechanical (B, n ¼ 5e12) sensitivities were
assessed by acetone and von Frey filament tests, respectively, before injections and biweekly after. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the vehicle-treated mice
without tadalafil; #P < 0.05 compared with the L-OHP-treated mice without tadalafil (A, Tukey's post hoc test following two-way repeated measured ANOVA; B, Dunn's post hoc test
following KruskaleWallis test). (C) Thermal sensitivity was assessed by Hargreaves test after 8 weeks of repeated injections (n ¼ 5e8). ***P < 0.001 (Tukey's post hoc test following
one-way ANOVA). (DeF) The current perception thresholds (mA) eliciting paw withdrawal responses to the sine-wave pulses at 5 Hz (A; C fiber), 250 Hz (B; Ad fiber), and
2000 Hz (C; Ab fiber) were measured after 8 weeks of repeated injections (n ¼ 8e13). *P < 0.05, ***P < 0.001 (Tukey's post hoc test following one-way ANOVA). The results are
expressed as means ± S.E.M.
Fig. 4. Effect of tadalafil on L-OHP-induced decreases in nerve conduction. L-OHP (10 mg/
kg) or its vehicle (Veh) was injected i.p. once a week for 8 weeks, during which mice
were fed normal chow or a chow diet containing 0.1% tadalafil (TDF). Sensory (A) and
motor (B) NCVs were measured in the mouse tails (n ¼ 8e13). ***P < 0.001 (Tukey's
post hoc test following one-way ANOVA). The results are expressed as means ± S.E.M.
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cold hypersensitivity can be mitigated by an increase in peripheral
blood flow. We recently showed that hypoxia resulting from pe-
ripheral vascular impairment sensitizes TRPA1 in diabetic periph-
eral neuropathy and hindlimb ischemic mouse models.15,34 Thus, it
is conceivable that the acute effect of vasodilators on cold hyper-
sensitivity may be mediated by a suppression of hypoxia-induced
TRPA1 sensitization. By contrast, a single administration of tada-
lafil had no effect on the L-OHP-induced mechanical hypersensi-
tivity, consistent with our previous findings in diabetic neuropathy
and hindlimb ischemic mouse models.34
The key finding of this study is that the progressive improve-
ments of peripheral vascular impairment and rewarming by
tadalafil attenuated a variety of symptoms associated with OIPN,
including mechanical, cold, and current hypersensitivities, thermal
hypoesthesia, decreased sensory NCV and microvessel density, and
axon degeneration in the sciatic nerves. These inhibitory effects are
unlikely to be caused by the altered blood concentration and
accumulation of L-OHP in peripheral neurons. Mechanical, cold,
and current hypersensitivities are generally considered to be
mediated through the sensitization of nociceptors and enhanced
excitability of nociceptive primary sensory neurons (peripheral
sensitization), as well as synaptic facilitation and enhanced
responsiveness of nociceptive dorsal horn neurons (central sensi-
tization). Peripheral and central sensitization in OIPN are
Fig. 5. Effect of tadalafil on L-OHP-induced decrease in the density of endoneurial microvessels in the sciatic nerve. L-OHP (10 mg/kg) or its vehicle (Veh) was injected i.p. once a week for
8 weeks, during which mice were fed normal chow or a chow diet containing 0.1% tadalafil (TDF). (A) Representative confocal fluorescence photographs of CD31-immunoreactive
staining of endoneurial microvessels in cross-sections of sciatic nerves. Scale bar ¼ 100 mm (20 mm in an enlarged image). (B) Quantitative analysis of the density of CD31-
immunoreactive vessels (number/mm2) (n ¼ 5e11). *P < 0.05, **P < 0.01 (Tukey's post hoc test following one-way ANOVA). The results are expressed as means ± S.E.M.
Fig. 6. Effect of tadalafil on L-OHP-induced axonal degeneration in the sciatic nerve. L-OHP (10 mg/kg) or its vehicle was injected i.p. once a week for 8 weeks, during which mice were
fed normal chow or a chow diet containing 0.1% tadalafil (TDF). (A) Representative electron light micrographs of cross-sections of the sciatic nerves from vehicle- and L-OHP-treated
mice with or without tadalafil. Scale bar ¼ 10 mm. (B) Quantitative analysis of the distribution of axon circularity in the sciatic nerves. The percentages of the myelinated fibers
showing axon circularity >0.7, between 0.5 and 0.7, and <0.5 are presented (n ¼ 7e10). *P < 0.05 (Tukey's post hoc test following one-way ANOVA). The results are expressed as
means ± S.E.M.
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considered to be due to alterations of voltage-gated ion channels
and TRP channels, dysregulation of calcium homeostasis, spinal
glial activation and so on.1,3 However, taken together with the
findings that mechanical hypersensitivity was not affected by
transient vasodilatory effect of tadalafil, it is conceivable that
continuous preservation of peripheral blood flow might prevent
the induction and/or progression of OIPN, resulting prevention of
peripheral and central sensitization, rather than inhibition of these
enhanced pain signaling. Pain in OIPN can be inhibited by analge-
sics or drugs available for neuropathic pain.35 In this context, the
guideline for chemotherapy-induced peripheral neuropathy
moderately recommends a serotonin noradrenalin reuptake in-
hibitor duloxetine, and may offer to try tricyclic antidepressants, or
gabapentin/pregabalin, while it also describes that these drugs
have no effect on hypoesthesia and no preventive effect on OIPN.35
Our findings further suggest that long-term administration of
tadalafil prevents OIPN, rather than simply providing analgesic
effects.
Several lines of evidence suggest that impaired endoneurial
microvascular function and the resultant perineural hypoxia and
malnutrition contribute to the pathogenesis of peripheral
neuropathy.5,6 Perineural hypoxia caused by decreased nerve blood
flow alters nerve function, and exacerbates nerve degeneration
through production of oxidative stress.36 Moreover, increased
oxidative stress causes further endoneurial microvascular
dysfunction.6,37 Notably, oxidative stress from mitochondrial
dysfunction is a major cause of L-OHP-induced neurotoxicity,38 and
antioxidants can reduce OIPN.39 In this way, endoneurial micro-
vascular dysfunction may contribute to the progression of L-OHP-
induced neurotoxicity. Our present data showed that tadalafil
administration inhibited the reduced number of CD31-
immunoreactive microvessels in the sciatic nerves, suggesting
that tadalafil can preserve L-OHP-induced endoneurial microvas-
cular dysfunction. This conservation of the endoneurial environ-
ment and thus prevention of perineural hypoxia and malnutrition
may contribute to the preservation of axon morphology in sciatic
nerves. It may be interesting to determine whether tadalafil
administration can reduce the level of oxidative stress in OIPN
model mice. However, we could not fully exclude other mecha-
nisms, such as direct protective effects of tadalafil on primary
sensory neurons and/or surrounding myelinated Schwann cells.
Further investigations are needed to identify the underlying
mechanisms.
By contrast, we and other groups recently reported that reduc-
tion of peripheral blood flow by cooling or compressing the ex-
tremities with frozen or surgical gloves can suppress taxanes-
induced peripheral neuropathy in breast cancer patients.40,41 The
cryotherapy or compression therapy seemingly contradicts the
present results. However, they are performed to prevent the dis-
tribution of the anti-cancer agent into the extremities only just
before, during and after the intravenous infusion. When the blood
concentration of L-OHP is high, intake of vasodilators is likely to
increase the distribution into the peripheral area, and to possibly
exacerbate OIPN. Thus, it may be better to prevent OIPN by stop-
ping vasodilators before, during and after L-OHP injection, but by
recovering peripheral blood flow when the blood concentration of
L-OHP is low.
In conclusion, the results from the present studies show that
the improvement of peripheral vascular impairment by tadalafil, a
PDE5 inhibitor, alleviates cold hypersensitivity and prevents the
progression of OIPN, resulting in inhibition of abnormal sensa-
tions, neurological dysfunction and morphological neuro-
degeneration. Furthermore, we confirmed that tadalafil do not
impact the antitumor effect of L-OHP in vitro. Although it will be
needed to determine whether continuous increase in blood flow
affects tumor growth and antitumor effect of L-OHP in tumor-
bearing animal experiments, our data suggest that vasodilators,
such as tadalafil, are potential therapeutic and preventive options
for OIPN.
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Fig. 7. Effect of tadalafil on L-OHP-induced cytotoxicity in cultured human cancer cell
lines. HCT116 (A) and AGS (B) human cancer cell lines were incubated with vehicle
(0.1% DMSO; control) or L-OHP (10 mM) for 24 h in the presence or absence of tadalafil
(TDF; 1e10 mM). Then, the cell viability was measured by an MTT assay. The results are
expressed as percentages relative to control cells (n ¼ 4e5). **P < 0.01, ***P < 0.001
compared with the control cells (Tukey's post hoc test following two-way ANOVA). The
results are expressed as means ± S.E.M.
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